XML 17 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]    
Revenues $ 43,488 $ 589,462
Research and development expenses (Note 11) 3,032,863 3,207,466
Selling and Marketing (Note 12) 1,092,462 1,525,168
General and administrative expenses (Note 13) 2,456,763 6,432,679
Total operating expenses 6,582,088 11,165,313
Operating loss 6,538,600 10,575,851
Financing income (expense), net (Note 14) (176,820) 247,045
Loss for the period 6,715,420 10,328,806
Other comprehensive income:    
Foreign currency translation adjustment 53,557 48,099
Comprehensive Loss for the period $ 6,661,863 $ 10,280,707
Loss per share (Basic) (Note 16) $ (4.74) $ (1.87)
Loss per share (Diluted) (Note 16) $ (4.74) $ (1.87)
Common shares used in computing Basic Loss per share (Note 16) 8,396,847 6,285,324
Common shares used in computing Diluted Loss per share (Note 16) [1] 8,396,847 6,285,324
[1] In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2018, management considered, among other things, a valuation prepared by a third-party valuation firm following the occurrence of the Forced Conversion. For December 31, 2017 management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series D Units and Series C Units (See Note 10C).